E-LIB Suche - Ergebnisse für: Bang, Yung-Jue

1

Inflamed immune phenotype predicts favorable clinical outco..:

Shen, Jeanne ; Choi, Yoon-La ; Lee, Taebum...
Journal for ImmunoTherapy of Cancer. 12 (2024) 2 - p. e008339 , 2024

Link: https://doi.org/10.1136/..

2

Zolbetuximab plus chemotherapy for locally advanced unresec..:

Shitara, Kohei ; Shah, Manish A. ; Lordick, Florian...
Future Oncology. , 2024

Link: https://doi.org/10.1080/..

3

A Phase 1b/2a Study of GC1118 with 5-Fluorouracil, Leucovor..:

Lee, Keun-Wook ; Han, Sae-Won ; Kim, Tae Won...
Cancer Research and Treatment. 56 (2024) 2 - p. 590-601 , 2024

Link: https://doi.org/10.4143/..

4

Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in..:

Shitara, Kohei ; Rha, Sun Young ; Wyrwicz, Lucjan S...
The Lancet Oncology. 25 (2024) 2 - p. 212-224 , 2024

Link: https://doi.org/10.1016/..

5

Trastuzumab deruxtecan in patients with human epidermal gro..:

Takahashi, Shunji ; Bando, Hideaki ; Kinoshita, Ichiro...
Japanese Journal of Clinical Oncology. 54 (2024) 4 - p. 434-443 , 2024

Link: https://doi.org/10.1093/..

6

Paclitaxel therapeutic drug monitoring - International asso..:

Hertz, Daniel L. ; Joerger, Markus ; Bang, Yung-Jue...
European Journal of Cancer. 202 (2024) - p. 114024 , 2024

Link: https://doi.org/10.1016/..

7

Trastuzumab deruxtecan in HER2-positive advanced gastric ca..:

Shitara, Kohei ; Bang, Yung-Jue ; Iwasa, Satoru...
Nature Medicine. , 2024

Link: https://doi.org/10.1038/..

8

Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gas..:

Shah, Manish A. ; Shitara, Kohei ; Ajani, Jaffer A....
Nature Medicine. 29 (2023) 8 - p. 2133-2141 , 2023

Link: https://doi.org/10.1038/..

9

ILUSTRO: Phase II Multicohort Trial of Zolbetuximab in Pati..:

Klempner, Samuel J. ; Lee, Keun-Wook ; Shitara, Kohei...
Clinical Cancer Research. 29 (2023) 19 - p. 3882-3891 , 2023

Link: https://doi.org/10.1158/..

10

Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positi..:

Shitara, Kohei ; Lordick, Florian ; Bang, Yung-Jue...
The Lancet. 401 (2023) 10389 - p. 1655-1668 , 2023

Link: https://doi.org/10.1016/..

11

Tusamitamab Ravtansine in Patients with Advanced Solid Tumo..:

Tabernero, Josep ; Bedard, Philippe L. ; Bang, Yung-Jue...
Cancer Research Communications. 3 (2023) 8 - p. 1662-1671 , 2023

Link: https://doi.org/10.1158/..

12

INTEGRATE II: randomised phase III controlled trials of reg..:

Lam, Lyn Ley ; Pavlakis, Nick ; Shitara, Kohei...
BMC Cancer. 23 (2023) 1 - p. , 2023

Link: https://doi.org/10.1186/..

13

Dabrafenib plus trametinib in BRAFV600E-mutated rare cancer..:

Subbiah, Vivek ; Kreitman, Robert J. ; Wainberg, Zev A....
Nature Medicine. 29 (2023) 5 - p. 1103-1112 , 2023

Link: https://doi.org/10.1038/..

14

First-In-Human Phase I Study of the OX40 Agonist MOXR0916 i..:

Kim, Tae Won ; Burris III, Howard A. ; de Miguel Luken, Maria J....
Clinical Cancer Research. 28 (2022) 16 - p. 3452-3463 , 2022

Link: https://doi.org/10.1158/..

15

Randomized, Double-Blind, Placebo-Controlled Phase III Stud..:

Shah, Manish A. ; Shitara, Kohei ; Lordick, Florian...
Clinical Cancer Research. 28 (2022) 17 - p. 3686-3694 , 2022

Link: https://doi.org/10.1158/..